🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Whether you call it a moment of clarity or a light bulb moment, for some, psychedelic assisted therapy can help them realise their purpose in life 💡 📺 'Psychedelics: Stepping into the Unknown' with @pliknaitzky | Premieres tomorrow 8:40pm on SBS and SBS On Demand

$IXHL Incannex Healthcare Inc. is one of the LONG positions in the $PSIL AdvisorShares Psychedelics #ETF #long #psychedelics #stocks #equities #investments #ketamine #MentalHealth #Psilocybin #mdma #stocksonthemove Learn more at PSIL.AdvisorShares.com

Incannex Healthcare (#nasdaq $IXHL) documentary on its PsiGAD #psilocybin assisted psychotherapy clinical trial program lead by principal investigator Dr Paul Liknaitzky featured in the film called “PSYCHEDELICS: Stepping Into The Unknown. sbs.com.au/ondemand/watch…

youtube.com/watch?v=cGEm8O… Incannex Healthcare Inc. Incannex Healthcare Inc (NASDAQ:$IXHL) is a clinical-stage pharmaceutical company developing proprietary new treatments for arthritis. With 28 distinct research and development programs and 6 clinical trials underway, the company is leveraging

Incannex Healthcare Inc. $IXHL Quarterly Update, Q1 2024 | NASDAQ (#cbd #thc #psychedelics #fda) nasdaq.com/press-release/…

Incannex ( $IXHL ) Completes Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder | #NASDAQ nasdaq.com/press-release/…

FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder $IXHL benzinga.com/markets/cannab… via Benzinga

youtu.be/4-zU69asnY0?si… Incannex Healthcare Inc. Incannex Healthcare Inc is developing a non-intrusive treatment for sleep apnea. With 28 distinct research and development programs and 6 clinical trials underway, Incannex is a busy clinical-stage pharmaceutical company developing proprietary

$IXHL Incannex Healthcare press release: Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea | #NASDAQ nasdaq.com/press-release/…

Incannex Healthcare Inc., a pharmaceutical company focused on developing medicinal #cannabinoid pharmacotherapies and psychedelic #medicine therapies, has commenced patient dosing in its phase 2/3 clinical trial to evaluate the safety and efficacy of IHL-42X for treating obstructive #SleepApnea

$IXHL Incannex press release: Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X #nasdaq #sleepapnea globenewswire.com/news-release/2…

$IXHL FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed (#nasdaq #FDA #psilocybin #anxiety) globenewswire.com/news-release/2…

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives $IXHL Ari Zoldan #arizoldan #incannex #joellatham #quantumresearchgroup #sleepapnea #Chemicals #Pharmaceutical #Banking #Biotechnology #FinancialServices… dlvr.it/TD19Xh

Australia’s Incannex Healthcare Inc. finalized a US$60 million dollar financing deal with New York’s investment firm Arena Investors, LP this week. $IXHL #StockMarketNews #cannabis #psychedelics #FinanceNews mugglehead.com/incannex-secur…

$IXHL Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer | #NASDAQ nasdaq.com/press-release/…

Incannex Healthcare ( $IXHL ) Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent Resmed | #NASDAQ nasdaq.com/press-release/…

Incannex Healthcare Makes Progress in Obstructive Sleep Apnea Research with Completion of Phase 2 Enrollment in the RePOSA Trial for IHL-42X Incannex Healthcare Inc. Incannex Healthcare Inc. (NASDAQ: $IXHL) #SleepApnea #IncannexHealthcare #Incannex #IHXL #StocksOnTheMove #StocksInNews #investors

Incannex ( $IXHL #Nasdaq ) Finishes Phase 2 Dosing for Sleep Apnea Drug, up 721% Topline results set for July as company gears up for pivotal #FDA meeting and Phase 3 Clinical Trial. #sleepapnea stocksurge.com.au/incannex-ixhl-…

Incannex Healthcare Inc. ( $IXHL ) Reports Fiscal Third Quarter 2025 Financial Results and Business Updates | #NASDAQ nasdaq.com/press-release/…

#IncannexHealthcare announces the appointment of four experts to its IHL-42X #ObstructiveSleepApnea (OSA) Clinical Advisory Board, including: Scott Sands, Ph.D., Ali Azarbarzin, Ph.D., Lora McGill, M.D., FAAN, and Nancy Collop, M.D. Read more: bit.ly/3HohHrs $IXHL